H. Yin

First name
H.
Last name
Yin
Abrahami, D., Pradhan, R., Yin, H., Yanofsky, R., McDonald, E. G., Bitton, A., & Azoulay, L. (2023). Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study. Gut. http://doi.org/10.1136/gutjnl-2022-328866
Pradhan, R., Lu, S., Yin, H., H. Y. Yu, O., Ernst, P., Suissa, S., & Azoulay, L. (2022). Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. Bmj, 379, e071380. http://doi.org/10.1136/bmj-2022-071380
Suissa, K., Schneeweiss, S., Douros, A., Yin, H., Patorno, E., & Azoulay, L. (2022). Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Res Clin Pract, 192, 110094. http://doi.org/10.1016/j.diabres.2022.110094
Abrahami, D., Tesfaye, H., Yin, H., Vine, S., Hicks, B., H. Y. Yu, O., et al. (2022). Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care. http://doi.org/10.2337/dc22-1174
Pradhan, R., Yin, H., H. Y. Yu, O., & Azoulay, L. (2022). Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc22-0712
Lu, S., Yin, H., H. Y. Yu, O., & Azoulay, L. (2022). Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients with Type 2 Diabetes. Epidemiology. http://doi.org/10.1097/ede.0000000000001486
Chowdhury, R., Michaud, J., H. Y. Yu, O., Yin, H., Azoulay, L., & Renoux, C. (2022). Effectiveness and safety of apixaban vs. rivaroxaban in patients with atrial fibrillation and type 2 diabetes mellitus. Thromb Haemost. http://doi.org/10.1055/a-1798-2116
Pradhan, R., Patorno, E., Tesfaye, H., Schneeweiss, S., Yin, H., Franklin, J., et al. (2022). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study. Am J Epidemiol. http://doi.org/10.1093/aje/kwac021
Pradhan, R., Yin, H., Yu, O., & Azoulay, L. (2022). Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc21-1953
Azoulay, L., Yin, H., Renoux, C., & Suissa, S. (2011). The use of atypical antipsychotics and the risk of breast cancer. Breast Cancer Res Treat. http://doi.org/10.1007/s10549-011-1506-2